

## **PIVALATE PHASE 2 DATA IN BRAIN METS TRIAL TO BE PRESENTED AT 34th EORTC/AACR/NCI Symposium in Barcelona (26-28 October 2022)**

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that interim data from Imperial College London’s F-18 Pivalate Phase 2a imaging trial in brain metastases, funded by the Medical Research Council will be presented at 34th EORTC/AACR/NCI symposium in Barcelona (26-28 October 2022) as well as being published in a peer-reviewed journal.

Radiopharm acquired an exclusive worldwide licence for the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London, and has a Sponsored Research Agreement on new analogues with its inventor Professor Eric Aboagye.

“We are very pleased to see a new molecule and an innovative mode of action in an area of high unmet medical need and we cannot wait to see the data presented” said Radiopharm’s CEO & Managing Director Riccardo Canevari.

“The team at Imperial College London, led by Professor Aboagye, did a tremendous job. F18-Pivalate and its potential therapeutic variations, currently under development, represent a promising theranostic approach to target brain metastases and potentially other brain tumors.”

Professor Aboagye added: “We’re very excited to present our interim data soon. A potentially innovative and effective new imaging approach will be more than welcomed in this field.”

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

### **For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**ASX ANNOUNCEMENT**  
**21 September 2022**



**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>